The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody supposed...
The U.S. Meals and Drug Administration (FDA) has accepted Enhertu (fam-trastuzumab deruxtecan-nxki) together with Perjeta (pertuzumab) for the first-line remedy of adults...
